biostudies-literatureUnknown60(6)Mendes REOritavancin (MIC50/90, 0.03/0.06 to 0.12 μg/ml) had potent activity against linezolid-resistant staphylococci, as well as Enterococcus faecalis and Enterococcus faecium (oritavancin MIC50/90, 0.015/0.12 μg/ml against both species). All linezolid-resistant isolates were inhibited by oritavancin at ≤0.12 μg/ml. These results confirmed the absence of cross-resistance between linezolid and oritavancin in staphylococci and enterococci.Antimicrobial agents and chemotherapy3817-20https://www.ebi.ac.uk/biostudies/studies/S-EPMC4879412biostudies-literatureOritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results.PMC4879412Farrell DJMendes REFlamm RKJones RNSader HSfalseOritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results.Oritavancin (MIC50/90, 0.03/0.06 to 0.12 μg/ml) had potent activity against linezolid-resistant staphylococci, as well as Enterococcus faecalis and Enterococcus faecium (oritavancin MIC50/90, 0.015/0.12 μg/ml against both species). All linezolid-resistant isolates were inhibited by oritavancin at ≤0.12 μg/ml. These results confirmed the absence of cross-resistance between linezolid and oritavancin in staphylococci and enterococci.2016-01-01T00:00:00Z2016 Jun2025-04-05T14:58:53.734Z2025-04-05T14:58:53.734ZS-EPMC48794122700182310.1128/aac.00281-1610.1128/AAC.00281-16